ORAL ANTIDIABETICS AND INSULINS DO NOT INCREASE CANCER RISK

Basit Öğe Kaydı
dc.contributor.authorAydın, Yusuf
dc.contributor.authorErden, Mücahit
dc.contributor.authorErmiş, Fatih
dc.contributor.authorKutlucan, Ali
dc.contributor.authorKaya, Ertuğrul
dc.contributor.authorAydın, Leyla Yılmaz
dc.contributor.authorCelbek, Gökhan
dc.date.accessioned2020-04-30T23:20:22Z
dc.date.available2020-04-30T23:20:22Z
dc.date.issued2013
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKaya, Ertugrul/0000-0003-0081-682Xen_US
dc.descriptionWOS: 000330151200043en_US
dc.description.abstractAims: To determine the effects of diabetes mellitus (DM) treatment regimens on malignancy. Methods: Six hundred fifty-five DM patients were enrolled. Patients receiving diabetes therapies for at least one year were retrospectively assessed with physical examination, detailed medical, habits, demographic characteristics and laboratory tests, and divided into two groups according to the diabetes treatment type (using oral agent or insulin and using metformin or not). Insulin users were grouped according to insulin regimens (intensive, basal and mixed) and to the insulin type (glargine, detemir, human insulin, biphasic analogue). Cancer cases were identified at the first visit. Results: Among 655 DM patients 13 (2%) were Type 1 DM, 642 (98%) were Type 2 DM; 379 (58%) were female, 276 (42%) were male. Thirty-sir cancers and 76 benign tumors were observed. Patients with and without a cancer were compared for diabetes treatment regimens and types of agents. No significant differences were observed between groups using oral agent or insulin (p=0.429) and using metformin or not (p=0.119). There were no significant differences between groups according to insulin regimens (p=0.059) and the insulin type (p=0.418). Conclusion: There was no significant difference in terms of cancer risk between different types of pharmacological treatments of diabetes (including analog insulins).en_US
dc.identifier.endpage867en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue4en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage859en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3992
dc.identifier.volume29en_US
dc.identifier.wosWOS:000330151200043en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetes mellitusen_US
dc.subjectcanceren_US
dc.subjectinsulinen_US
dc.subjectinsulin glargineen_US
dc.subjectmetforminen_US
dc.subjectoral antidiabeticsen_US
dc.titleORAL ANTIDIABETICS AND INSULINS DO NOT INCREASE CANCER RISKen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3992.pdf
Boyut:
1.55 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu